Speeda Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Purified rabies vaccine (vero cell)

Indications/Uses

Pre- & post-exposure vaccination against rabies.

Click to view Speeda detailed prescribing information

Dosage/Direction for Use

IM 0.5 mL in deltoid for adult & in anterio-lateral region of thigh for infant & toddler. Intradermal 0.1 mL (per site) in each deltoid. Pre-exposure schedule Primary vaccination: 3 inj on days 0, 7 & 28 (inj schedule on day 28 may be administered on day 21). Booster inj: 1 yr later then every 5 yr. Post-exposure schedule Non-immunized subject IM 5 inj (0.5 mL) on days 0, 3, 7, 14 & 28. Intradermal 1 dose (0.1 mL) at 2 different sites (usually left & right upper arm) on days 0, 3, 7 & 28. Immunized subject w/ pre-exposure full course immunity w/in 1 yr, or pre-exposure & booster immunity 1 yr later w/in 3 yr 1 dose on days 0 & 3 respectively in case of another exposure. Immunized subject w/ pre-exposure immunity but no booster inj after 1 yr, or post-exposure full course immunity 1 yr before, or pre-exposure & booster immunity 1 yr later but is over 3 yr Full course vaccination in case of another exposure.

Click to view Speeda detailed prescribing information

Overdosage

View Speeda overdosage for action to be taken in the event of an overdose.

Contraindications

Pre-exposure immunization: Avoid use in patient who has seriously chronic disease, nervous system disease, serious hypersensitivity or has allergic history to antibiotic or biological product. Delay vaccination in patient who is pregnant or in active period of acute fever.

Click to view Speeda detailed prescribing information

Special Precautions

Do not inj IV. IM: Do not inj in gluteal region. Not to be administered SC. Intradermal: Administer a new dose immediately if dose is inadvertently given SC or IM. Do not use in individuals receiving long term corticosteroid, other immunosuppressive therapy or chloroquine; immunocompromised individuals; individuals, particularly childn, w/ severe wounds especially to the head & neck or presenting late for consultation.

Click to view Speeda detailed prescribing information

Use In Pregnancy & Lactation

Click to view Speeda detailed prescribing information

Adverse Reactions

Local reaction eg, pain, redness, edema, pruritus & inj site induration. Systemic reaction eg, little fever, chill, asphyxia, atony, giddy, arthralgia, muscle pain, GI disorder. Serious adverse reaction eg, rare anaphylaxis eg, tetter, nettle rash.

Click to view Speeda detailed prescribing information

Drug Interactions

Ab produced can be affected by corticosteroid & immune inhibitor & can cause failed immunization.

Click to view Speeda detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Speeda detailed prescribing information

Storage

View Speeda storage conditions for details to ensure optimal shelf-life.

Description

View Speeda description for details of the chemical structure and excipients (inactive components).

Action

View Speeda mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BG01 - rabies, inactivated, whole virus ; Belongs to the class of rabies viral vaccines.

Regulatory Classification

Presentation/Packing

Form

Speeda freeze-dried powd for inj 2.5 IU

Packing/Price

(+ 0.5 mL diluent) 5 × 1's

Speeda

rabies vaccine

Manufacturer:

Liaoning Chengda Biotechnology

Distributor:

Pharma-Surrey